Rambam Signs Agreement with Biomica for Clinical Trial of Microbiome-based Immuno-oncology Drug
October 28, 2021 – Biomica’s immuno-oncology program is based on the premise that the gut microbiome affects the efficacy of cancer immunotherapy. The study is pending approval by Israel’s Ministry of Health. Rambam Health Care Campus recently signed a clinical trial agreement with Evogene Ltd. subsidiary Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based…